Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich's Ataxia Aged 2 to < 16 Years

NCT06953583 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT06953583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06953583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich's Ataxia Aged 2 to < 16 Years
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 9, 2025
Completion date
November 22, 2029
Enrollment
255 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich ataxia